Skip to content
DraconiticResearch
Search Sources API
190,332 studies31 sourcesUpdated 28 min ago
Peer-reviewedLicence not statedImmunotherapy

Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors

  • A. Dodi1
  • G. Mazzaschi1,2
  • F. Pecci1,2
  • P. Tamarozzi1,2
  • L. Moron Dalla Tor2
  • P. Bordi1
  • G. Iovane1,2
  • M. Manini1,2
  • M. Peroni1,2
  • F. Trentini1,2
  • S. D’agnelli1,2
  • G. Martines2
8 more authors
  • M. Pluchino1,2
  • M. Verzè1,2
  • R. Minari1
  • F. Perrone1
  • A. Leonetti1
  • F. Quaini2
  • N. Sverzellati3
  • M. Tiseo1,2
  1. 1Medical Oncology Unit, University Hospital of Parma, Parma, Italy
  2. 2Department of Medicine and Surgery, University of Parma, Parma, Italy
  3. 3Unit of Radiological Sciences, Department of Medicine and Surgery, University of Parma, Parma, Italy
Read full textDOICite

Related

  1. Baseline intratumoral TCRbeta; and TCRgamma; repertoires predict response to immune checkpoint inhibitors in advanced renal cell carcinoma
    M. Pino Gonzalez, M. E. Lazaro Quintela, G. d. V. Oria de Rueda +10
    medRxivPreprintCC BY-NC-NDFull textHuman geneticsmedRxiv
  2. The SChISM study: Circulating cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
    Linh Nguyen Phuong, Frederic Fina, Laurent Greillier +10
    HALPreprintCC BY-NC-SA 4.0Full textMolecular biology & gene regulationBioinformatics & computational biologyHAL
  3. Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
    Alessandro Russo, Christian Rolfo, Mariacarmela Santarpia
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  4. Evidence for Dose Optimization of Immune Checkpoint Inhibitors.
    Sewanti Limaye, Vanita Noronha, Kumar Prabhash
    Journal of immunotherapy and precision oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework
    Joe-Elie Salem, Stephane Ederhy, Meiying Zhang +1
    JACC: CardioOncologyPeer-reviewedCC BY-NC-ND 4.0Full text1 citedOncologyPMC

Cite

BibTeXRIS
BibTeX
@article{dodi2026baseline,
  title = {{Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors}},
  author = {A. Dodi and G. Mazzaschi and F. Pecci and P. Tamarozzi and L. Moron Dalla Tor and P. Bordi and G. Iovane and M. Manini and M. Peroni and F. Trentini and S. D’agnelli and G. Martines and M. Pluchino and M. Verzè and R. Minari and F. Perrone and A. Leonetti and F. Quaini and N. Sverzellati and M. Tiseo},
  journal = {Immunotherapy},
  year = {2026},
  month = oct,
  doi = {10.1080/1750743x.2026.2738332},
  url = {https://doi.org/10.1080/1750743x.2026.2738332},
}
RIS
TY  - JOUR
TI  - Baseline circulating immunophenotype as a predictor of immune-related adverse events in NSCLC patients treated with immune checkpoint inhibitors
AU  - A. Dodi
AU  - G. Mazzaschi
AU  - F. Pecci
AU  - P. Tamarozzi
AU  - L. Moron Dalla Tor
AU  - P. Bordi
AU  - G. Iovane
AU  - M. Manini
AU  - M. Peroni
AU  - F. Trentini
AU  - S. D’agnelli
AU  - G. Martines
AU  - M. Pluchino
AU  - M. Verzè
AU  - R. Minari
AU  - F. Perrone
AU  - A. Leonetti
AU  - F. Quaini
AU  - N. Sverzellati
AU  - M. Tiseo
PY  - 2026
DA  - 2026/10/11
JO  - Immunotherapy
DO  - 10.1080/1750743x.2026.2738332
UR  - https://doi.org/10.1080/1750743x.2026.2738332
SN  - 1750-743X
SN  - 1750-7448
ER  -